Please login to the form below

Not currently logged in
Email:
Password:

Nycomed markets Bonviva drug in Asia

Nycomed has become marketing authorisation holder of osteoporosis treatment Bonviva in key Asia-Pacific countries

Nycomed has completed the transfer of marketing authorisation approval for osteoporosis treatment Bonviva (Ibandronate) in a number of key Asia Pacific markets.

The licensing and supply agreement with Roche covers China, Hong Kong, Malaysia, Australia, New Zealand, Philippines, Singapore, Taiwan and Vietnam, with a future option to commercialise Bonviva in additional Asia Pacific territories.

Under the terms of the deal, Nycomed will hold marketing authorisation holder in all the licensed territories. Bonviva is a bisphosphonate used in the treatment of osteoporosis in post-menopausal women.

Financial details of the agreement were not disclosed.

Guido Oelkers, executive vice-president of commercial operations, said: "The in-licensing of Bonviva from Roche is another important step towards Nycomed's expansion in the Asia Pacific region and demonstrates our growing attraction as a marketing partner for leading companies and brands in these dynamic countries.”

Nycomed recently opened offices in China, South Korea, Indonesia, Malaysia and the Philippines.

15th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

We're award-winning joint working specialists. We help our clients to transform healthcare through effective collaboration, and deliver work to feel...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics